ECCO 2021 – New Data On Therapy For Severely Active Ulcerative Colitis

Returning guest, Dr. Bruce Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai discusses new data presented at the 16th Congress of European Crohn’s and Colitis Organisation (ECCO) from a trial evaluating biologic induction and maintenance therapy for moderately to severely active ulcerative colitis.

Bruce E. Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai is the study spokesperson for the three-year data from the long-term extension (LTE) of UNIFI, a Phase 3 protocol designed to evaluate the safety and efficacy of STELARA induction and maintenance dosing for the treatment of moderately to severely active ulcerative colitis in adults who demonstrated an inadequate response to or were unable to tolerate conventional (e.g., corticosteroids, immunomodulators) or biologic (e.g., one or more TNF blockers or vedolizumab) therapies. Dr. Sands’ clinical research includes treating inflammatory bowel disease and clinical investigations of new therapeutics. He serves as a reviewer for the New England Journal of Medicine and is a fellow of the American College of Gastroenterology and the American Gastroenterological Association.